Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ManNAc in Primary Podocyte Diseases
NCT02639260Phase 1Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of n-acetylmannosamine in minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN) (2 cohorts), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Safety assessed by self-reported symptoms and standard laboratory testing and ManNAc and sialic acid metabolism related to ManNAc. Started Jul 2016; status: completed.
02
Drugs
n-acetylmannosamine
03
Conditions
minimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT02639260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639260.